Efficacy and cost-effectiveness of darbepoetin alfa once every 4 weeks versus continuous erythropoietin receptor activator once every 4 weeks for anemia correction in patients with chronic kidney disease not on dialysis.
Geo Neul ParkKyung Ho LeeJi Eun MoonSoo Jeong ChoiMoo Yong ParkJin Kuk KimByung Chul YuPublished in: Kidney research and clinical practice (2024)
Once-in-4-weeks DA safely corrects anemia in erythropoiesis-stimulating agent-naïve patients with chronic kidney disease not on dialysis and is more cost-effective than once-in-4-weeks CERA.